hotspot -WSS

hotspot

author：fashion 2025-09-27 23:51:59 - browse：4

Cambridge: AbbVie — Ruby Wallau for STAT

AbbVie will pay $10 billion for the biotech firm Immunogen, the company said Thursday, acquiring an approved treatment for ovarian cancer and buying into a burgeoning area of oncology.

Under the agreement, AbbVie will pay $31.26 per share in cash for Immunogen, a nearly 100% premium to the company’s recent trading price. Central to the deal, expected to close in the middle of next year, is Elahere, an Immunogen product that won Food and Drug Administration approval for advanced ovarian cancer in 2022.

Elahere is among a surging class of cancer medicines called antibody-drug conjugates, or ADCs, which are designed to deliver a targeted dose of chemotherapy directly to tumor cells while sparing healthy tissues. AbbVie’s acquisition is the latest multibillion-dollar deal in the space, following Merck’s $22 billion agreement with ADC specialist Daiichi Sankyo and Pfizer’s $43 billion buyout of Seagen earlier this year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Sports medicine is finally prioritizing gender equality

leisure time

hotspot

WSS

Guidelines to prevent youth baseball injuries need more muscle

DIEP, the 'gold standard' of breast reconstruction, is under threat

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

Moonlake's readout produced a cash windfall. Risks remain

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

Dario to buy mental health app maker Twill in cash and stock deal

knowledge

hotspot

focus

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Medical leaders decry Supreme Court decision on affirmative action

Dobbs anniversary: the lost opportunity of abortion as health care

DIEP, the 'gold standard' of breast reconstruction, is under threat

Apple is now the first public company to be valued at $3 trillion

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Walensky prepares to leave CDC — and Congress — behind

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

focus

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

23andMe had bad news about my health. I wish a person had delivered it

In utero gene editing: an explainer

Dario to buy mental health app maker Twill in cash and stock deal

ChatGPT in medicine: STAT answers readers' burning questions

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

entertainment

leisure time

hotspot

explore